Effect of Concurrent Gonadotropin-Releasing Hormone Agonist Treatment on Dose and Side Effects of Gender-Affirming Hormone Therapy in Adolescent Transgender Patients

Rachel K. Jensen; Jennifer K. Jensen; Lisa K. Simons; DIane Chen; Ilina Rosoklija; Courtney A. Finlayson

doi:10.1089/trgh.2018.0061

Effect of Concurrent Gonadotropin-Releasing Hormone Agonist Treatment on Dose and Side Effects of Gender-Affirming Hormone Therapy in Adolescent Transgender Patients

Rachel K. Jensen^*, Jennifer K. Jensen, Lisa K. Simons, DIane Chen, Ilina Rosoklija, Courtney A. Finlayson

^*Corresponding author for this work

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

This retrospective chart review aims to address gaps in the literature regarding the efficacy and interaction of gonadotropin-releasing hormone agonists (GnRHa) and gender-affirming hormone therapies in medical transition regimens in transgender adolescents. We abstracted and reviewed data from 83 patients at our pediatric gender clinic, and found that patients who initiated treatment with GnRHa before gender-affirming hormones (estrogen, testosterone) required lower doses of those hormones than those who did not use GnRHa. The results of this preliminary research provide a foundation for future long-term prospective studies aimed to better understand these relationships.

Original language	English (US)
Pages (from-to)	300-303
Number of pages	4
Journal	Transgender Health
Volume	4
Issue number	1
DOIs	https://doi.org/10.1089/trgh.2018.0061
State	Published - Oct 1 2019

Keywords

gender-affirming hormone dose
gender-affirming hormone side effect
puberty blocker
transgender youth

ASJC Scopus subject areas

Gender Studies
Medicine (miscellaneous)

Access to Document

10.1089/trgh.2018.0061

Cite this

@article{1d4a2be4ac6d413aafdfa1a6fbdbca81,

title = "Effect of Concurrent Gonadotropin-Releasing Hormone Agonist Treatment on Dose and Side Effects of Gender-Affirming Hormone Therapy in Adolescent Transgender Patients",

abstract = "This retrospective chart review aims to address gaps in the literature regarding the efficacy and interaction of gonadotropin-releasing hormone agonists (GnRHa) and gender-affirming hormone therapies in medical transition regimens in transgender adolescents. We abstracted and reviewed data from 83 patients at our pediatric gender clinic, and found that patients who initiated treatment with GnRHa before gender-affirming hormones (estrogen, testosterone) required lower doses of those hormones than those who did not use GnRHa. The results of this preliminary research provide a foundation for future long-term prospective studies aimed to better understand these relationships.",

keywords = "gender-affirming hormone dose, gender-affirming hormone side effect, puberty blocker, transgender youth",

author = "Jensen, {Rachel K.} and Jensen, {Jennifer K.} and Simons, {Lisa K.} and DIane Chen and Ilina Rosoklija and Finlayson, {Courtney A.}",

note = "Publisher Copyright: {\textcopyright} Rachel K. Jensen et al. 2019; Published by Mary Ann Liebert, Inc. 2019.",

year = "2019",

month = oct,

day = "1",

doi = "10.1089/trgh.2018.0061",

language = "English (US)",

volume = "4",

pages = "300--303",

journal = "Transgender Health",

issn = "2380-193X",

publisher = "Mary Ann Liebert Inc.",

number = "1",

}

TY - JOUR

T1 - Effect of Concurrent Gonadotropin-Releasing Hormone Agonist Treatment on Dose and Side Effects of Gender-Affirming Hormone Therapy in Adolescent Transgender Patients

AU - Jensen, Rachel K.

AU - Jensen, Jennifer K.

AU - Simons, Lisa K.

AU - Chen, DIane

AU - Rosoklija, Ilina

AU - Finlayson, Courtney A.

N1 - Publisher Copyright: © Rachel K. Jensen et al. 2019; Published by Mary Ann Liebert, Inc. 2019.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - This retrospective chart review aims to address gaps in the literature regarding the efficacy and interaction of gonadotropin-releasing hormone agonists (GnRHa) and gender-affirming hormone therapies in medical transition regimens in transgender adolescents. We abstracted and reviewed data from 83 patients at our pediatric gender clinic, and found that patients who initiated treatment with GnRHa before gender-affirming hormones (estrogen, testosterone) required lower doses of those hormones than those who did not use GnRHa. The results of this preliminary research provide a foundation for future long-term prospective studies aimed to better understand these relationships.

AB - This retrospective chart review aims to address gaps in the literature regarding the efficacy and interaction of gonadotropin-releasing hormone agonists (GnRHa) and gender-affirming hormone therapies in medical transition regimens in transgender adolescents. We abstracted and reviewed data from 83 patients at our pediatric gender clinic, and found that patients who initiated treatment with GnRHa before gender-affirming hormones (estrogen, testosterone) required lower doses of those hormones than those who did not use GnRHa. The results of this preliminary research provide a foundation for future long-term prospective studies aimed to better understand these relationships.

KW - gender-affirming hormone dose

KW - gender-affirming hormone side effect

KW - puberty blocker

KW - transgender youth

UR - http://www.scopus.com/inward/record.url?scp=85074522962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074522962&partnerID=8YFLogxK

U2 - 10.1089/trgh.2018.0061

DO - 10.1089/trgh.2018.0061

M3 - Article

C2 - 31663037

AN - SCOPUS:85074522962

SN - 2380-193X

VL - 4

SP - 300

EP - 303

JO - Transgender Health

JF - Transgender Health

IS - 1

ER -

Effect of Concurrent Gonadotropin-Releasing Hormone Agonist Treatment on Dose and Side Effects of Gender-Affirming Hormone Therapy in Adolescent Transgender Patients

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this